Frazier Life Sciences Management L.P. bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 1,184,840 shares of the company’s stock, valued at approximately $15,758,000. Frazier Life Sciences Management L.P. owned 1.93% of Dyne Therapeutics at […]
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) COO Susanna Gatti High sold 80,000 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $30.24, for a total value of $2,419,200.00. Following the completion of the transaction, the chief operating officer now owns 154,062 […]
Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) have received a consensus rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price […]
Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target boosted by Chardan Capital from $31.00 to $42.00 in a research report sent to investors on Tuesday, MarketBeat Ratings reports. They currently have a buy rating on the stock. Other equities research analysts also recently issued reports about the company. Stifel Nicolaus increased their price […]
Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target boosted by Jefferies Financial Group from $36.00 to $42.00 in a research note released on Monday, Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock. DYN has been the topic of several other research reports. Morgan Stanley assumed coverage on Dyne […]